Plasmalyte-148 Solution and Blood Coagulation

Seoul National University Hospital12 enrolled

Overview

Fluids administered intravenously may alter whole blood coagulation. However, little is known about the dose-response relationships of hemodilution in plasmalyte-148 solution. Investigators have therefore performed the present study to measure the effect of a plasmalyte-148 solution on the coagulation pathway according to the hemodilution level using a rotational thromboelastometry (ROTEM®) tests.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Blood Coagulation Disorder

Interventions

Plasmalyte-148OTHER

Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers * Age: 20 to 65 years * Body weight \> 50 kg * Volunteers who provided informed consent Exclusion Criteria: * Hematologic disease * Anticoagulant medication

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Outcomes

Primary Outcomes

FIBTEM

Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.

Time frame: During the rotational thromboelastometry analysis/ an average of 1 hour

Secondary Outcomes

INTEM

Intrinsic pathway values of rotational thromboelastometry analysis/ INTEM is not an acronym.

Time frame: During the rotational thromboelastometry analysis/ an average of 1 hour

EMTEM

Extrinsic pathway values of rotational thromboelastometry analysis/ EXTEM is not an acronym.

Time frame: During the rotational thromboelastometry analysis/ an average of 1 hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.